The Endocrine Society has issued clinical guidance on the pharmacological treatment of obesity. In the past two years the FDA has approved four new anti-obesity drugs – lorcaserin, phentermine/topiramate, naltrexone/bupropion and liraglutide. Medications approved for chronic weight management can be useful adjuncts to lifestyle change for patients who have been unsuccessful with diet and exercise alone, the ...
New guidelines on treating obesity
16 Jan 2015